{"id":785,"date":"2022-01-10T22:30:09","date_gmt":"2022-01-10T22:30:09","guid":{"rendered":"https:\/\/kellyintel.com\/?p=785"},"modified":"2024-01-26T15:52:14","modified_gmt":"2024-01-26T15:52:14","slug":"xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases","status":"publish","type":"post","link":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/","title":{"rendered":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases"},"content":{"rendered":"<p>The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA.<\/p>\n<p>From <a href=\"https:\/\/www.barrons.com\/articles\/pfizer-beam-therapeutics-gene-editing-diseases-partnership-51641678989\">Barron&#8217;s<\/a>:<\/p>\n<blockquote><p>Gene editing is the next phase of genetic medicine, and another big step was just announced. Monday morning, <span class=\"quote-pick\" data-track-hover=\"QuotePeek\" data-charting-symbol=\"STOCK\/US\/XNYS\/PFE\"> Pfizer<\/span> unveiled a $1.3 billion partnership with <span class=\"quote-pick\" data-track-hover=\"QuotePeek\" data-charting-symbol=\"STOCK\/US\/XNAS\/BEAM\"> Beam Therapeutics<\/span> to develop three treatments for genetic disease in the next four years. They\u2019ll use Beam\u2019s leading-edge technology that makes precise corrections to typographical errors in our genes\u2014a <a class=\"icon none inline-hover\" href=\"https:\/\/www.barrons.com\/articles\/a-new-gene-editing-technique-may-be-able-to-help-children-who-prematurely-age-51609948802?&amp;mod=article_inline\" target=\"_blank\" rel=\"follow noopener\">technology called \u201cbase editing\u201d<\/a>.<\/p><\/blockquote>\n<p>Beam is a top constituent in the <a href=\"https:\/\/kellyintel.com\/xdna\">XDNA Index<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA. From Barron&#8217;s: Gene editing is the next phase of genetic medicine, and another big step was [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":786,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence\" \/>\n<meta property=\"og:description\" content=\"The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA. From Barron&#8217;s: Gene editing is the next phase of genetic medicine, and another big step was [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Kelly Intelligence\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-10T22:30:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-26T15:52:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kevin Kelly\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@kellyintel\" \/>\n<meta name=\"twitter:site\" content=\"@kellyintel\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kevin Kelly\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\"},\"author\":{\"name\":\"Kevin Kelly\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8\"},\"headline\":\"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases\",\"datePublished\":\"2022-01-10T22:30:09+00:00\",\"dateModified\":\"2024-01-26T15:52:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\"},\"wordCount\":121,\"publisher\":{\"@id\":\"https:\/\/kellyintel.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg\",\"articleSection\":[\"CRISPR &amp; Gene Editing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\",\"url\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\",\"name\":\"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence\",\"isPartOf\":{\"@id\":\"https:\/\/kellyintel.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg\",\"datePublished\":\"2022-01-10T22:30:09+00:00\",\"dateModified\":\"2024-01-26T15:52:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage\",\"url\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg\",\"contentUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kellyintel.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kellyintel.com\/#website\",\"url\":\"https:\/\/kellyintel.com\/\",\"name\":\"Kelly Intelligence\",\"description\":\"Traditional Investing. Innovative Thinking.\",\"publisher\":{\"@id\":\"https:\/\/kellyintel.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kellyintel.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kellyintel.com\/#organization\",\"name\":\"Kelly Intelligence\",\"url\":\"https:\/\/kellyintel.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg\",\"contentUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg\",\"width\":2085,\"height\":1042,\"caption\":\"Kelly Intelligence\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/twitter.com\/kellyintel\",\"https:\/\/www.linkedin.com\/company\/kellyintel\",\"https:\/\/www.youtube.com\/channel\/UCv_XTXFT8t4ZpPBqmMcvxXA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8\",\"name\":\"Kevin Kelly\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g\",\"caption\":\"Kevin Kelly\"},\"url\":\"https:\/\/kellyintel.com\/author\/kevin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/","og_locale":"en_US","og_type":"article","og_title":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence","og_description":"The breaking news this week in gene editing was Pfizer Inc. will pay as much as $1.35 billion to partner with Beam Therapeutics Inc. on developing drugs for rare genetic diseases using base editing, a technology for manipulating DNA. From Barron&#8217;s: Gene editing is the next phase of genetic medicine, and another big step was [&hellip;]","og_url":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/","og_site_name":"Kelly Intelligence","article_published_time":"2022-01-10T22:30:09+00:00","article_modified_time":"2024-01-26T15:52:14+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg","type":"image\/jpeg"}],"author":"Kevin Kelly","twitter_card":"summary_large_image","twitter_creator":"@kellyintel","twitter_site":"@kellyintel","twitter_misc":{"Written by":"Kevin Kelly","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#article","isPartOf":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/"},"author":{"name":"Kevin Kelly","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8"},"headline":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases","datePublished":"2022-01-10T22:30:09+00:00","dateModified":"2024-01-26T15:52:14+00:00","mainEntityOfPage":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/"},"wordCount":121,"publisher":{"@id":"https:\/\/kellyintel.com\/#organization"},"image":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg","articleSection":["CRISPR &amp; Gene Editing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/","url":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/","name":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases - Kelly Intelligence","isPartOf":{"@id":"https:\/\/kellyintel.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage"},"image":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg","datePublished":"2022-01-10T22:30:09+00:00","dateModified":"2024-01-26T15:52:14+00:00","breadcrumb":{"@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#primaryimage","url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg","contentUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/CRISPR-GENE-EDITING-XDNA-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/kellyintel.com\/xdna-pfizer-and-beam-partner-to-develop-treatments-for-3-genetic-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kellyintel.com\/"},{"@type":"ListItem","position":2,"name":"XDNA: Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/kellyintel.com\/#website","url":"https:\/\/kellyintel.com\/","name":"Kelly Intelligence","description":"Traditional Investing. Innovative Thinking.","publisher":{"@id":"https:\/\/kellyintel.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kellyintel.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kellyintel.com\/#organization","name":"Kelly Intelligence","url":"https:\/\/kellyintel.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/","url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg","contentUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg","width":2085,"height":1042,"caption":"Kelly Intelligence"},"image":{"@id":"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/twitter.com\/kellyintel","https:\/\/www.linkedin.com\/company\/kellyintel","https:\/\/www.youtube.com\/channel\/UCv_XTXFT8t4ZpPBqmMcvxXA"]},{"@type":"Person","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8","name":"Kevin Kelly","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g","caption":"Kevin Kelly"},"url":"https:\/\/kellyintel.com\/author\/kevin\/"}]}},"_links":{"self":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/785"}],"collection":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/comments?post=785"}],"version-history":[{"count":4,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/785\/revisions"}],"predecessor-version":[{"id":790,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/785\/revisions\/790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/media\/786"}],"wp:attachment":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/media?parent=785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/categories?post=785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/tags?post=785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}